BioRegenx

BRGX

Information Technology Services · Technology

Price

$0.01

+0.00 (+0.00%)

Market Cap

$7.4M

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+255.8% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 269.7M (2021) → 959.7M (2025)

BioRegenx is a small healthcare company focused on personalized health and wellness solutions. It sells products and services built around genetic and biological data, helping individuals understand how their body responds to nutrition, lifestyle, and aging. The company operates in the growing field of precision health, where science is used to tailor recommendations to each person rather than offering one-size-fits-all advice.

BioRegenx earns revenue through product sales and service fees, likely including testing kits and digital health tools, which helps explain its high gross margin of around 82%. The company appears to operate primarily in the United States and is very small, with a market cap near zero, meaning it carries significant financial risk. Its negative operating margin shows it is spending more than it earns from operations, and the key challenge ahead is scaling revenue fast enough to reach profitability before it runs out of resources.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-16.3% YoY

YoY Growth Rate

Revenue declining

EPS Growth

+94.7% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$0/ year

0.0% of revenue

Below sector average (15%)

Research and development spending

Insider Activity

73.4%ownership

↑ Rising

Insiders increasing their stake — aligned with shareholders

Cash Position

Cash flow positive

$69,383 cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

BioRegenx's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

82.7%

Premium pricing power — 82.7% gross margin

Operating Margin

-54.6%

Losing money on operations — -54.6%

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

-23.0%

Shrinking sales (-23.0% YoY)

EPS YoY

N/A

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

1.6%

Thin free cash flow (1.6%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial